Secins – Cytohesin Inhibitors
Compounds for the inhibition of EGFR-signalling.
Invention: Pharmacological inhibition of cell proliferation, adhesion and migration is pivotal in the treatment of a wide variety of cancers. A prominent protein involved in these processes and associated with the onset of cancer in humans is the EGF receptor. It was surprisingly found by the inventors that cytohesins are a pathophysiologically relevant class of cytoplasmatic EGFR activators. Therefore, they are an attractive target for the modulation of different disease-relevant signal transduction pathways. A correlation of cytohesin expression with EGFR-signalling could already be shown for human lung adenocarcinoma. By cytohesin inhibition, therapeutic interventions may be possible in the future. The present invention discloses small molecules which combine a highly selective inhibitory effect on cytohesins with cell permeability and low toxicity.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Superradiant atoms could push the boundaries of how precisely time can be measured
Superradiant atoms can help us measure time more precisely than ever. In a new study, researchers from the University of Copenhagen present a new method for measuring the time interval,…
Ion thermoelectric conversion devices for near room temperature
The electrode sheet of the thermoelectric device consists of ionic hydrogel, which is sandwiched between the electrodes to form, and the Prussian blue on the electrode undergoes a redox reaction…
Zap Energy achieves 37-million-degree temperatures in a compact device
New publication reports record electron temperatures for a small-scale, sheared-flow-stabilized Z-pinch fusion device. In the nine decades since humans first produced fusion reactions, only a few fusion technologies have demonstrated…
